Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
Functionally active antithrombin can be quantified by chromogenic substrate assays utilizing the heparin cofactor activity of antithrombin and the inhibition rates of thrombin or of activated factor X (FXa). Thrombin-based assays but not FXa-based assays may overestimate the antithrombin activity due to their sensitivity toward heparin cofactor II. We focused on the question whether an overestimation of antithrombin activity by thrombin-based assays involves the risk of misdiagnosing antithrombin-deficient individuals as being non-deficient. We determined antithrombin using two thrombin-based assays and one FXa-based assay in 27 plasma samples from patients with acquired antithrombin deficiency spiked with lepirudin, in antithrombin-deficient plasma and in mixtures of antithrombin-deficient plasma and normal plasma. We also measured antithrombin in healthy subjects, in patients with inherited and acquired antithrombin deficiency and in patients under high-dose heparin treatment. At therapeutic final concentrations of lepirudin, antithrombin activities were considerably overestimated by the thrombin-based assays but not by the FXa-based assay. The residual antithrombin activities in antithrombin-deficient plasma determined by the thrombin-based assays were markedly higher than the corresponding values obtained with the FXa-based assay. The thrombin-based assays also overestimated antithrombin activity in patients under high-dose heparin. However, the degree of overestimation in the range between 50 and 100 IU/dl was too low to misidentify individuals with inherited or acquired antithrombin deficiency as normal. We conclude that functionally active antithrombin can be reliably determined using FXa-based chromogenic substrate assays in all settings examined. Thrombin-based assays must not be used in patients under treatment with hirudin or other direct thrombin inhibitors.
Beeck
H
H
Institute of Hemostaseology and Transfusion Medicine, City Hospital, Ludwigshafen, Germany.
Nagel
D
D
Pindur
G
G
Scharrer
I
I
Preiss
A
A
Seiler
D
D
Hellstern
P
P
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000097:blood; D000991:Antithrombins / Q000172:deficiency / Q000187:drug effects / Q000378:metabolism*; D002863:Chromogenic Compounds / Q000592:standards*; D003276:Contraceptives, Oral / Q000097:blood / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015951:Factor Xa; D005260:Female; D006493:Heparin / Q000097:blood / Q000494:pharmacology; D006629:Hirudins / Q000031:analogs & derivatives / Q000097:blood; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D011933:Reagent Kits, Diagnostic; D011994:Recombinant Proteins / Q000097:blood; D012016:Reference Values; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013917:Thrombin
D000925:Anticoagulants; D000991:Antithrombins; D002863:Chromogenic Compounds; D003276:Contraceptives, Oral; D006629:Hirudins; D011933:Reagent Kits, Diagnostic; D011994:Recombinant Proteins; D006493:Heparin; D013917:Thrombin; D015951:Factor Xa; C083544:lepirudin